383 related articles for article (PubMed ID: 23892525)
1. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.
Markar SR; Bodnar A; Rosales J; Song G; Low DE
Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525
[TBL] [Abstract][Full Text] [Related]
2. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
[TBL] [Abstract][Full Text] [Related]
3. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
4. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
5. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
6. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
8. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
9. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
10. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
11. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
[TBL] [Abstract][Full Text] [Related]
12. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
13. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
[TBL] [Abstract][Full Text] [Related]
14. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
15. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
16. Multimodal treatment strategy for clinical T3 thoracic esophageal cancer.
Saeki H; Morita M; Tsuda Y; Hidaka G; Kasagi Y; Kawano H; Otsu H; Ando K; Kimura Y; Oki E; Kusumoto T; Maehara Y
Ann Surg Oncol; 2013 Dec; 20(13):4267-73. PubMed ID: 23943036
[TBL] [Abstract][Full Text] [Related]
17. Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEER-Medicare analysis.
Hong JC; Murphy JD; Wang SJ; Koong AC; Chang DT
Ann Surg Oncol; 2013 Nov; 20(12):3999-4007. PubMed ID: 23800897
[TBL] [Abstract][Full Text] [Related]
18. Physiology, not chronology, dictates outcomes after esophagectomy for esophageal cancer: outcomes in patients 80 years and older.
Markar SR; Low DE
Ann Surg Oncol; 2013 Mar; 20(3):1020-6. PubMed ID: 23117475
[TBL] [Abstract][Full Text] [Related]
19. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals.
Merkow RP; Bilimoria KY; McCarter MD; Chow WB; Ko CY; Bentrem DJ
Ann Surg Oncol; 2012 Feb; 19(2):357-64. PubMed ID: 21769460
[TBL] [Abstract][Full Text] [Related]
20. Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
Spierings LE; Lagarde SM; van Oijen MG; Gisbertz SS; Wilmink JW; Hulshof MC; Meijer SL; Anderegg MC; van Berge Henegouwen MI; van Laarhoven HW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S766-71. PubMed ID: 26350367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]